Abeona Therapeutics Inc Total Assets
Abeona Therapeutics Inc total assets. Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) holds total assets worth $179.51 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ABEO market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Abeona Therapeutics Inc (1995–2025)
Total assets of Abeona Therapeutics Inc from 1995 to 2025. This chart illustrates how Abeona Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See ABEO live share price for real-time trading data and today's change.
Abeona Therapeutics Inc - Asset Composition Analysis
Abeona Therapeutics Inc Total Assets Breakdown (December 2025)
Abeona Therapeutics Inc total assets breakdown as of December 2025. Abeona Therapeutics Inc's total assets of $179.51 Million consist of 93.3% current assets and 6.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.7% |
| Accounts Receivable | $6.71 Million | 3.1% |
| Inventory | $5.49 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Abeona Therapeutics Inc (ABEO) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abeona Therapeutics Inc's current assets represent 93.3% of total assets in 2025, a decrease from 100.0% in 1995.
- Cash Position: Cash and equivalents constituted 35.7% of total assets in 2025, down from 88.7% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.
Abeona Therapeutics Inc Competitors by Total Assets
Key competitors of Abeona Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Abeona Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.63 | 6.73 | 2.57 |
| Quick Ratio | 6.40 | 6.65 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $139.77 Million | $197.75 Million | $41.43 Million |
Abeona Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Abeona Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | 101.6% |
| Total Assets | $219.57 Million |
| Market Capitalization | $241.32 Million USD |
Valuation Analysis
Above Book Valuation: The market values Abeona Therapeutics Inc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Abeona Therapeutics Inc's assets grew by 101.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual total assets of Abeona Therapeutics Inc from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $219.57 Million | +101.57% |
| 2024-12-31 | $108.93 Million | +70.20% |
| 2023-12-31 | $64.00 Million | -0.33% |
| 2022-12-31 | $64.21 Million | -19.31% |
| 2021-12-31 | $79.59 Million | -47.36% |
| 2020-12-31 | $151.20 Million | -32.31% |
| 2019-12-31 | $223.38 Million | +28.09% |
| 2018-12-31 | $174.40 Million | -2.44% |
| 2017-12-31 | $178.77 Million | +60.97% |
| 2016-12-31 | $111.06 Million | +38.73% |
| 2015-12-31 | $80.06 Million | +382.78% |
| 2014-12-31 | $16.58 Million | +2605.06% |
| 2013-12-31 | $613.00K | -64.57% |
| 2012-12-31 | $1.73 Million | -54.29% |
| 2011-12-31 | $3.79 Million | -56.85% |
| 2010-12-31 | $8.77 Million | +454.07% |
| 2009-12-31 | $1.58 Million | -62.05% |
| 2008-12-31 | $4.17 Million | -54.41% |
| 2007-12-31 | $9.15 Million | +42.37% |
| 2006-12-31 | $6.43 Million | -10.91% |
| 2005-12-31 | $7.21 Million | -34.96% |
| 2004-12-31 | $11.09 Million | -6.10% |
| 2003-12-31 | $11.81 Million | -39.39% |
| 2002-12-31 | $19.49 Million | -23.54% |
| 2001-12-31 | $25.49 Million | -16.51% |
| 2000-12-31 | $30.53 Million | +563.61% |
| 1999-12-31 | $4.60 Million | +91.67% |
| 1998-12-31 | $2.40 Million | +65.86% |
| 1997-12-31 | $1.45 Million | -70.64% |
| 1996-12-31 | $4.93 Million | +131.47% |
| 1995-12-31 | $2.13 Million | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more